Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 188.64 USD 1.65%
Market Cap: 333.7B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ABBV stock under the Base Case scenario is 144 USD. Compared to the current market price of 188.64 USD, Abbvie Inc is Overvalued by 24%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ABBV Relative Value
Base Case
144 USD
Overvaluation 24%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.8
P/S
P/S
Price to Sales
5.8
vs History
12
vs Industry
54
Median 3Y
4.6
Median 5Y
4.2
Industry
6.9
Forward
5.4
More Details
77.3
P/E
P/E
Price to Earnings
77.3
vs History
4
vs Industry
2
Median 3Y
37.8
Median 5Y
28.9
Industry
22.4
Forward
14.9
More Details
17.4
P/OCF
P/OCF
Price to OCF
17.4
vs History
12
vs Industry
10
Median 3Y
11.4
Median 5Y
9.9
Industry
19.1
More Details
14.9
P/FCFE
P/FCFE
Price to FCFE
14.9
vs History
50
vs Industry
10
Median 3Y
16.6
Median 5Y
15.3
Industry
23.2
More Details
98.5
P/B
P/B
Price to Book Value
98.5
vs History
4
vs Industry
0
Median 3Y
20.2
Median 5Y
15.4
Industry
2.5
More Details
6.8
EV/S
EV/S
Enterprise Value to Sales
6.8
vs History
11
vs Industry
42
Median 3Y
5.6
Median 5Y
5.2
Industry
7.5
Forward
6.3
More Details
9.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
9.7
vs History
14
vs Industry
37
Median 3Y
7.8
Median 5Y
7.5
Industry
8.9
More Details
15.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
15.4
vs History
12
vs Industry
8
Median 3Y
11.3
Median 5Y
11.1
Industry
4
Forward
12.6
More Details
23.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
23.2
vs History
12
vs Industry
6
Median 3Y
16.5
Median 5Y
16.5
Industry
3.7
Forward
13.4
More Details
20.3
EV/OCF
EV/OCF
Enterprise Value to OCF
20.3
vs History
11
vs Industry
8
Median 3Y
13.3
Median 5Y
12.7
Industry
4.5
More Details
21.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
21.4
vs History
11
vs Industry
7
Median 3Y
13.8
Median 5Y
13.3
Industry
3.4
More Details
3.9
EV/IC
EV/IC
Enterprise Value to IC
3.9
vs History
4
vs Industry
32
Median 3Y
3.1
Median 5Y
2.8
Industry
4.6
More Details

Multiples Across Competitors

ABBV Competitors Multiples
Abbvie Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Abbvie Inc
NYSE:ABBV
327.6B USD 5.8 77.3 15.4 23.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 341 491.5 -167 972.9 -203 972.6 -201 645
US
Amgen Inc
NASDAQ:AMGN
146.1B USD 4.4 35.7 14.8 26.3
US
Gilead Sciences Inc
NASDAQ:GILD
122.3B USD 4.3 254.8 10.1 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
110.4B USD 10 -206.1 22.3 23.4
US
Epizyme Inc
F:EPE
94.1B EUR 1 993.4 -508.7 -553.9 -539.1
AU
CSL Ltd
ASX:CSL
115.2B AUD 4.9 27 16.6 20.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60B USD 4.2 13.6 8.1 9.1
US
Seagen Inc
F:SGT
39.3B EUR 19.2 -58.9 -63.4 -57.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
33.7B USD 14.4 -125.6 -554.5 -277.9
NL
argenx SE
XBRU:ARGX
30.5B EUR 15.6 41.1 -2 325.6 -1 559.2
P/S Multiple
Revenue Growth P/S to Growth
US
Abbvie Inc
NYSE:ABBV
Average P/S: 3 213 051.6
5.8
7%
0.8
FR
Pharnext SCA
OTC:PNEXF
35 341 491.5
N/A N/A
US
Amgen Inc
NASDAQ:AMGN
4.4
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.3
3%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10
10%
1
US
E
Epizyme Inc
F:EPE
1 993.4
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
6%
0.7
US
S
Seagen Inc
F:SGT
19.2
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.4
29%
0.5
NL
argenx SE
XBRU:ARGX
15.6
39%
0.4
P/E Multiple
Earnings Growth PEG
US
Abbvie Inc
NYSE:ABBV
Average P/E: 74.9
77.3
87%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -167 972.9 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
35.7
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
254.8
187%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -206.1 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -508.7 N/A N/A
AU
CSL Ltd
ASX:CSL
27
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -125.6 N/A N/A
NL
argenx SE
XBRU:ARGX
41.1
28%
1.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Abbvie Inc
NYSE:ABBV
Average EV/EBITDA: 14.6
15.4
14%
1.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -203 972.6 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.8
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
7%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.3
18%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -553.9 N/A N/A
AU
CSL Ltd
ASX:CSL
16.6
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
8.1
14%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.4 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -554.5 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 325.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Abbvie Inc
NYSE:ABBV
Average EV/EBIT: 19.2
23.2
29%
0.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 645 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
26.3
31%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.4
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -539.1 N/A N/A
AU
CSL Ltd
ASX:CSL
20.8
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.1
13%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -277.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 559.2 N/A N/A

See Also

Summary
ABBV intrinsic value, competitors valuation, and company profile.
DCF Valuation
ABBV stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ABBV stock valuation using valuation multiples.
Wall Street Estimates
ABBV price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ABBV stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.